Literature DB >> 33026059

Comment on: Adrenal hypoplasia congenita in identical twins.

Alia M Al Amer1, Khloud M Al Rubaya.   

Abstract

[No Abstract Available].

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33026059      PMCID: PMC7841517          DOI: 10.15537/smj.2020.10.25391

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


To the Editor Follow up of the case report “Adrenal hypoplasia congenita in identical twins”, published in Saudi Medical Journal in January 2019.1 The case was about a monozygotic twin brothers who presented at different ages with different presentations with confirmed genetic testing of DAX1 (NR0B1) mutation. Adrenal hypoplasia congenita is frequently associated with hypogonadotropic hypogonadism, the spectrum of presentation varies widely from pubertal failure to infertility. The twin brothers were followed up in endocrine clinic every 3 to 4 months and their pubertal development was assessed in each visit, with the assessment of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone level every 6 months. Both of them proceeded smoothly in normal puberty. Their last visit was on June 2020. Their growth parameter based on CDC growth chart: Twin A: height = 147 cm (3rd centile), weight: 33 kg (below 3rd centile), Pubertal staging: testes Tanner stage IV & pubic hair Tanner stage III (). Twin A’s laboratory results. Twin B: height = 147 cm (3rd centile), weight: 43 kg (below 10th centile), Pubertal staging: testes Tanner stage IV & pubic hair Tanner stage III (). Twin B’s laboratory results. Both of them proceeded smoothly in normal puberty. In conclusion, our case study for the twin brothers with adrenal hypoplasia congenita, that both of them were having normal pubertal development.
Table 1

Twin A’s laboratory results.

Table 2

Twin B’s laboratory results.

  1 in total

1.  Adrenal hypoplasia congenita in identical twins.

Authors:  Alia M Al Amer; Khloud M Al Rubaya; Ali S Alzahrani
Journal:  Saudi Med J       Date:  2019-01       Impact factor: 1.484

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.